Dimethyl fumarate (DMF), a fumaric acid with antioxidant and immunomodulatory properties, is among the most commonly used oral therapies for relapsing multiple sclerosis (MS). Progressive multifocal leukoencephalopathy (PML) has been associated with several disease-modifying therapies (DMTs), including DMF in treating MS. We present detailed clinical characteristics of nine PML cases and show that the PML incidence in DMF-treated patients is 0.02 per 1000 patients. In addition to persistent severe lymphopenia, older age appears to be a potential risk for PML. However, younger patients without lymphopenia were also observed to develop PML. DMF-associated PML has occurred in patients with absolute lymphocyte counts (ALCs) above the guideline threshold, suggesting that changes in specific subsets might be more important than total ALC. Furthermore, since DMF has been found to decrease immune cell migration by decreasing the expression of adhesive molecules, the cerebrospinal fluid (CSF) immune profile may also be useful for assessing PML risk in DMF-treated patients. This review provides an up-to-date assessment of PML cases occurring in DMF-treated patients and discusses other potential considerations in light of our current understanding of DMF’s mechanism of action on the immune system in the periphery and in the central nervous system (CNS).
BergerJRAksamitAJCliffordDB, et al. PML diagnostic criteria: Consensus statement from the AAN neuroinfectious disease section. Neurology2013; 80: 1430–1438.
2.
MarkowitzRBThompsonHCMuellerJF, et al. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis1993; 167(1): 13–20.
3.
FoxRJMillerDHPhillipsJT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087–1097.
4.
GoldRKapposLArnoldDL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367: 1098–1107.
5.
Kresa-ReahlKRepovicPRobertsonD, et al. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther2018; 40: 2077–2087.
6.
CohanSLMosesHCalkwoodJ, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord2018; 22: 27–34.
7.
WilliamsMJAmezcuaLOkaiA, et al. Real-world safety and effectiveness of dimethyl fumarate in Black or African American patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. Epub ahead of print 29May2020. DOI: 10.1007/s40120-020-00193-5.
8.
ChineaAAmezcuaLVargasW, et al. Real-world safety and effectiveness of dimethyl fumarate in Hispanic or Latino patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. Epub ahead of print 29May2020. DOI: 10.1007/s40120-020-00192-6.
9.
BergerJRCreeBAGreenbergB, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology2018; 90: e1815–e1821.
10.
BergerJRFoxRJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol2016; 22: 533–535.
11.
GieselbachRJMuller- HansmaAHWijburgMT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: A review of 19 cases. J Neurol2017; 264: 1155–1164.
12.
RosenkranzTNovasMTerborgC. PML in a patient with lymphocytopenia treated with dimethyl fumarate. New Engl J Med2015; 372: 1476–1478.
13.
BaharnooriMLyonsJDastagirA, et al. Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm2016; 3(5): e274.
14.
GarciaJChavez BaroniHDubessyAL, et al. Progressive multifocal leukoencephalopathy in a patient treated by dimethyl fumarate for multiple sclerosis with no lymphopenia but exhausted T lymphocyte subpopulations. In: Presented at the 35th congress of the European committee for treatment and research in multiple sclerosis and 24th annual conference of rehabilitation in MS, Stockholm, 12 September 2019.
15.
DieboldMAltersbergerVDécardBF, et al. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler2019; 25: 1682–1685.
16.
MotteJKneiphofJStraßburger-KrogiasK, et al. Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. J Neurol2018; 265(8): 1880–1882.
17.
PonnappanSPonnappanU. Aging and immune function: Molecular mechanisms to interventions. Antioxid Redox Signal2011; 14: 1551–1585.
18.
WengNP. Aging of the immune system: How much can the adaptive immune system adapt. Immunity2006; 24(5): 495–499.
19.
WeiGLiuCKAtwoodWJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol2000; 6: 127–136. DOI: 10.3109/13550280009013156.
20.
BrewBJDaviesNWCinqueP, et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol2010; 6(12): 667–679.
21.
EgliAInfantiLDumoulinA, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis2009; 199: 837–846.
22.
KitamuraTAsoYKuniyoshiN, et al. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis1990; 161(6): 1128–1133.
23.
AgostiniHTRyschkewitschCFStonerGL. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol1996; 34(1): 159–164.
24.
MajorEOYousryTACliffordDB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: A decade of lessons learned. Lancet Neurol2018; 17(5): 467–480.
25.
WortmanMJLundbergPSDagdanovaAV, et al. Opportunistic DNA recombination with Epstein–Barr virus at sites of control region rearrangements mediating JC virus neurovirulence. J Infect Dis2016; 213: 1436–1443.
26.
JohnsonEMWortmanMJDagdanovaAV, et al. Polyomavirus JC in the context of immunosuppression: A series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin Dev Immunol2013; 2013: 197807.
27.
DuraliDde Goër de HerveMGGasnaultJ, et al. B cells and progressive multifocal leukoencephalopathy: Search for the missing link. Front Immunol2015; 6: 241.
28.
MajorEOAmemiyaKTornatoreCS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev1992; 5: 49–73.
29.
PerkinsMRRyschkewitschCLiebnerJC, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. Plos Pathog2012; 8(11): e1003014.
30.
GheuensSBordEKesariS, et al. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol2011; 85(14): 7256–7263.
31.
MarzocchettiALimaMTompkinsT, et al. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. Virology2009; 383: 173–177.
SpencerCMCrabtree-HartmanECLehmann-HornK, et al. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm2015; 2(3): e76.
34.
WuQWangQMaoG, et al. Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients. J Immunology2017; 198: 3069–3080.
35.
GrossCCSchulte-MecklenbeckAKlinsingS, et al. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2016; 3(1): e183.
36.
LongbrakeEERamsbottomMJCantoniC, et al. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler2016; 22: 1061–1070.
37.
KornbergMDBhargavaPKimPM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science2018; 360: 449–453.
38.
ChamCMGajewskiTF. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol2005; 174: 4670–4677.
39.
ChamCMDriessensGO’KeefeJP, et al. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol2008; 38(9): 2438–2450.
40.
MacintyreANGerrietsVANicholsAG, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab2014; 20: 61–72.
41.
ChangCHCurtisJDMaggiLB, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell2013; 153: 1239–1251.
42.
GerrietsVAKishtonRJNicholsAG, et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest2015; 125(1): 194–207.
43.
WangRDillonCPShiLZ, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity2011; 35: 871–882.
44.
TannahillGMCurtisAMAdamikJ, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature2013; 496: 238–242.
45.
ShiLZWangRHuangG, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med2011; 208: 1367–1376.
46.
GhoreschiKBrückJKellererC, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med2011; 208: 2291–2303.
47.
LongbrakeEECantoniCChahinS, et al. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. Mult Scler2018; 24(6): 728–738.
48.
von GlehnFDias- CarneiroRPCMoraesAS, et al. Dimethyl fumarate downregulates the immune response through the HCA(2)/GPR109A pathway: Implications for the treatment of multiple sclerosis. Mult Scler Relat Disord2018; 23: 46–50.
49.
ChenHAssmannJCKrenzA, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest2014; 124(5): 2188–2192.
50.
ParodiBRossiSMorandoS, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol2015; 130(2): 279–295.
51.
HansonJGilleAZwykielS, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest2010; 120(8): 2910–2919.
52.
KalinskiP. Regulation of immune responses by prostaglandin E2. J Immunol2012; 188: 21–28.
53.
DieboldMSieversCBantugG, et al. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. J Autoimmun2018; 86: 39–50.
54.
PengHGuerau-de-ArellanoMMehtaVB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem2012; 287: 28017–28026.
55.
LundySKWuQWangQ, et al. Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol Neuroimmunol Neuroinflamm2016; 3(2): e211.
56.
LiRRezkAGhadiriM, et al. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J Immunol2017; 198: 691–698.
57.
SmithMDMartinKACalabresiPA, et al. Dimethyl fumarate alters B-cell memory and cytokine production in MS patients. Ann Clin Transl Neurol2017; 4(5): 351–355.
58.
KiharaYGrovesARiveraRR, et al. Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models. Ann Clin Transl Neurol2015; 2(10): 978–983.
59.
VandermeerenMJanssensSBorgersM, et al. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun1997; 234: 19–23.
60.
RubantSALudwigRJDiehlS, et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol2008; 128(2): 326–331.
61.
WallbrechtKDrickNHundAC, et al. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Exp Dermatol2011; 20: 980–985.
62.
Holm HansenRHøjsgaard ChowHChristensenJR, et al. Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis. Mult Scler Relat Disord2020; 37: 101451.
63.
FoxRJChanAGoldR, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurol Clin Pract2016; 6(3): 220–229.
64.
Lehmann-HornKPenkertHGreinP, et al. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?Neurology2016; 87: 440–441.
65.
MillsEAMao-DraayerY. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Mult Scler2018; 24(8): 1014–1022.
66.
LongbrakeEENaismithRTParksBJ, et al. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Mult Scler J Exp Transl Clin2015; 1: 96994.
67.
FoxRChanAGoldR, et al. Characterization of absolute lymphocyte count profiles in MS patients treated with delayed-release dimethyl fumarate: Considerations for patient management. In: Poster presented at the 68th annual meeting of the American academy of neurology, Vancouver, BC, Canada, 15–21 April 2016.
68.
GiulianiFLongbrakeEMao-DraayerY, et al. Immunomodulatory effects of DMF treatment on the peripheral lymphocyte compartment: A focus on older MS patients (478). Neurology2020; 94: 478.
69.
De-SimoneFISariyerROtaloraYL, et al. IFN-Gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression. PLoS ONE2015; 10(6): e0129694.
70.
MillsEAMao-DraayerY. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: A bird’s eye view. Front Immunol2018; 9: 138.
71.
StüveOCravensPDFrohmanEM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology2009; 72: 396–401.
72.
StüveOMarraCMJeromeKR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol2006; 59(5): 743–747.
73.
RempeTWangQWuQ, et al. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing. Neurol Neuroimmunol Neuroinflamm2020; 7: e709.
74.
HimedanMCamelo-PiraguaSMillsEA, et al. Pathologic Findings of chronic PML-IRIS in a patient with prolonged PML survival following natalizumab treatment. J Investig Med High Impact Case Rep2017; 5(3): 34248.
75.
WhiteFA3rdIshaqMStonerGL, et al. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol1992; 66(10): 5726–5734.
